Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-06952229 |
| Synonyms | |
| Therapy Description |
PF-06952229 is an inhibitor of the transforming growth factor-beta receptor 1 (TGFBR1), which results in stimulation of the immune system (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-06952229 | PF06952229|PF 06952229 | TGFBR1 inhibitor 16 | PF-06952229 is an inhibitor of the transforming growth factor-beta receptor 1 (TGFBR1), which results in stimulation of the immune system (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03685591 | Phase I | PF-06952229 Enzalutamide + PF-06952229 Letrozole + Palbociclib + PF-06952229 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | Terminated | USA | 0 |